| Adamas Pharmaceuticals focuses on therapies to reduce the burden of neurological diseases on patients, caregivers, and society. Co.'s product, GOCOVRI (amantadine) extended-release capsules, is for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Co.'s partnered product, Namzaric® (memantine hydrochloride extended release and donepezil hydrochloride) capsules, are for the treatment of moderate to severe dementia of an Alzheimer's type, marketed in the U.S. by Allergan plc under a license agreement between Co. and Forest Laboratories Holdings Limited, a subsidiary of Allergan plc. The ADMS YTD return is shown above.
The YTD Return on the ADMS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ADMS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADMS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.